leadf
logo-loader
viewKazia Therapeutics Ltd

Kazia Therapeutics soars on award of US FDA Fast Track Designation to paxalisib for glioblastoma

Fast Track Designation (FTD) is designed to expedite development of pharmaceutical products which demonstrate the potential to address unmet medical needs in serious or life-threatening conditions.

Kazia Therapeutics Ltd - Kazia Therapeutics receives US FDA Fast Track Designation to Paxalisib for Glioblastoma
Drugs with FTD are eligible to apply for Accelerated Approval and Priority Review at the time of a New Drug Application submission

Kazia Therapeutics Ltd (ASX:KZA) (NASDAQ:KZIA) soared almost 50% on being awarded US Food and Drug Administration (FDA) Fast Track Designation (FTD) to paxalisib for the treatment of glioblastoma – the most common and aggressive form of primary brain cancer.

FTD is designed to expedite development of pharmaceutical products which demonstrate the potential to address unmet medical needs in serious or life-threatening conditions.

It provides Kazia with enhanced access to FDA, including opportunities for face-to-face meetings and written consultation throughout the remaining development of paxalisib.

Shares jumped almost 50% today to A$1.235, a new four-year high for the innovative oncology-focused biotechnology company, before finishing the day up 35% at $1.12 on volume of almost 5 million.

“Powerful acknowledgement”

Chief executive officer James Garner said: “In awarding Fast Track Designation to paxalisib, FDA has recognised the drug’s potential to meaningfully improve outcomes for patients with glioblastoma.

“This is a very powerful acknowledgement.

“The opportunities that Fast Track Designation creates, as we move towards an NDA filing, are of great value and have the potential to substantially accelerate the commercialisation of paxalisib.

“The ‘rolling review’ process enables Kazia to complete and submit substantial sections of our NDA filing in advance, saving time and reducing risk for the product.

“We look forward to working closely with FDA as we move into the final stage of development for paxalisib.”

Drugs with FTD are eligible to apply for Accelerated Approval and Priority Review at the time of a New Drug Application (NDA) submission, which may result in faster product approval.

FTD also allows for ‘rolling review’, whereby Kazia may submit completed sections of the paxalisib NDA as they become available, rather than at the end of development.

Next steps

Kazia completed recruitment to its phase II clinical trial of paxalisib in newly diagnosed glioblastoma in February 2020, and interim clinical data was presented at the American Association of Cancer Research (AACR) Virtual Annual Meeting II in June 2020.

Overall survival was calculated at 17.7 months, which compares favourably to a historical figure of 12.7 months for temozolomide, the existing FDA-approved standard of care.

Kazia expects to present further data from this study in the later in the year before concluding the study in early 2021.

Paxalisib has been selected to join the international GBM AGILE pivotal study in glioblastoma and recruitment is expected to begin later in the year. 

Quick facts: Kazia Therapeutics Ltd

Price: 0.8075 AUD

ASX:KZA
Market: ASX
Market Cap: $92.98 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Kazia Therapeutics Ltd named herein, including the promotion by the Company of Kazia Therapeutics Ltd in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Kazia Therapeutics CEO hails Fast Track Designation for Paxalisib

Kazia Therapeutics Ltd's (ASX:KZA) (NASDAQ:KZIA) Dr James Garner caught up with Proactive's Andrew Scott following the news it's been awarded US Food and Drug Administration (FDA) Fast Track Designation (FTD) for Paxalisib for the treatment of glioblastoma – the most common and aggressive form...

on 21/8/20

2 min read